Space-filling intragastric implants with fluid flow
09895247 ยท 2018-02-20
Assignee
Inventors
- Mitchell H. Babkes (Santa Clarita, CA)
- Zachary P. Dominguez (Santa Barbara, CA)
- Justin Schwab (Santa Barbara, CA, US)
Cpc classification
A61F5/0073
HUMAN NECESSITIES
A61F5/0003
HUMAN NECESSITIES
Y10T24/44342
GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
A61F5/0076
HUMAN NECESSITIES
Y10T24/44564
GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
Y10T24/4453
GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
International classification
Abstract
A variety of passive intragastric implant devices for obesity treatment are disclosed. Such passive devices do not autonomously change shape, but instead react within the stomach to induce satiety. The devices may take up volume within the stomach, thus reducing the intake capacity. Additionally, the devices may contact areas within the stomach, such as the cardia surrounding the esophageal sphincter, to stimulate satiety-inducing nerves. Also, certain devices slow gastric emptying by blocking or otherwise impeding flow through the pyloric sphincter. A number of devices combine two or more of these satiety-inducing features. Methods of implant are disclosed including compressing the devices within a delivery tube and transorally advancing the devices through the esophagus to be deployed within the stomach. Removal of the devices occurs in the reverse.
Claims
1. A passive intragastric obesity treatment implant for placement within a stomach, comprising: a foam body, forming a portion of an outer surface of the implant, having a sufficient outer diameter so as to contact interior walls of the stomach upon contraction thereof, the foam body having an inner diameter defining a central throughbore of the foam body: a radially expandable and compressible stent lining the central throughbore, the stent having a tubular wall and struts across a proximal end to filter larger food particles, the implant being formed of a material which permits it to be compressed into a substantially linear delivery configuration and that will resist degradation over a period of at least six months within the stomach, wherein the central throughbore has a diameter between about 2-4 cm and the foam body has a thickness, measured between the outer diameter and the inner diameter, between about 6-18 cm.
2. The implant of claim 1, wherein the foam body has an outer diameter of between about 10-20 cm.
3. The implant of claim 1, wherein the struts extend inwardly and proximally at an angle from respective bases at the tubular wall to respective proximal ends at the proximal end of the stent, and further comprising a ring at the proximal end of the stent joining the proximal ends of the struts together, wherein the bases of the struts are connected to the tubular wall but are not connected directly together by a ring.
4. A passive intragastric obesity treatment implant for placement within the stomach, the implant consisting of: a radially expandable and collapsible tubular stent, the stent having a latticework tubular wall and interconnected struts that cross a proximal end of the stent and that permit radial compression and expansion and providing a filtered pathway that slows passage of food therethrough wherein the struts extend inwardly and proximally at an angle from respective bases at the tubular wall to respective proximal ends at the proximal end of the stent; and an annular foam body, forming a portion an outer surface of the implant, surrounding the stent and having a radial size to fill a space across the stomach, and an axial size that does not extend a full length of the stomach, the implant being formed of materials which permit it to be compressed into a substantially linear delivery configuration and that will resist degradation over a period of at least six months within the stomach wherein the foam body has a thickness that is greater than or equal to a diameter of the central throughbore.
5. The implant of claim 4, wherein the foam body has an outer diameter of between about 10-20 cm.
6. The implant of claim 5, wherein the foam body defines an inner bore in which the stent is received, the inner bore having a diameter between about 2-4 cm.
7. The implant of claim 6, wherein the foam body is annular and has a thickness between 6-18 cm.
8. The implant of claim 4, wherein the foam body has an axial dimension of between about 10-20 cm.
9. The implant of claim 4, wherein the stent is made from one of a rubber, fluorosilicone, fluoroelastomer, thermoplastic elastomer, thermoplastic, thermoset, metal, or any combination of the foregoing.
10. The implant of claim 4, wherein the foam body is an open cell foam.
11. The implant of claim 4, wherein the foam body is a closed cell foam.
12. The implant of claim 4, wherein the foam body in a relaxed, uncompressed configuration has a cylindrical outer surface, and a cylindrical inner bore that closely receives the stent.
13. The implant of claim 12, wherein the foam body has outwardly-projecting conical end surfaces.
14. The implant of claim 4, wherein the foam body is made from one of a rubber, fluorosilicone, fluoroelastomer, thermoplastic elastomer, or any combination of the foregoing.
15. The implant of claim 4, wherein the foam body defines an inner bore in which the stent is received, the inner bore having a diameter between about 2-4 cm.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
(1) Features and advantages of the present invention will become appreciated as the same become better understood with reference to the specification, claims, and appended drawings wherein:
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
(16)
(17)
(18)
(19)
(20)
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
(21) The present invention is directed to a variety of different intragastric devices that passively treat obesity by taking up space within the stomach or contact areas in and around the stomach to induce feelings of satiety. Furthermore, some devices described herein affect the rate of stomach emptying. It should be understood that a number of the disclosed devices provide more than one of these passive aspects, and also that any disclosed structure could be combined with another disclosed structure unless physically impossible. As such, combinations of the passive satiety-inducing features disclosed herein, even if not explicitly stated, are contemplated. The term passive refers primarily to a lack of any moving parts within the devices, but in general to the inert nature of the various devices. A passive device as defined herein, however, is not one that cannot affect change or stimulate the stomach, but rather one that may do so without any physical or chemical changes to its basic makeup.
(22)
(23) Lower down in the stomach the antrum connects the body to the pyloris, which leads into the duodenum. Below the stomach, the duodenum leads into the upper part of the small intestine (not shown); the jejunum makes up about one-third of the small intestine. The region of the stomach that connects to the duodenum is the pylorus. The pylorus communicates with the duodenum of the small intestine via the pyloric sphincter (valve). This valve regulates the passage of chyme from stomach to duodenum and it prevents backflow of chyme from duodenum to stomach.
(24) Certain devices disclosed herein have flow-through channels and entirely or almost-entirely fill the stomach. For instance, a stomach-in-stomach device 160 shown in
(25) The device 160 is a saline-filled, soft, balloon-like structure shown in a pre-implant state in
(26) Although the primary food pathway is forced through the central flow channel 168, some leakage around the device 160 will likely occur, which is acceptable. The grooves 167 in the outside walls of the device 160 help channel small solids and liquids to the smaller passages 170 that radiate toward the larger, central channel 168. Smaller particles and some liquids may pass directly into the pylorus through the scalloped atrium end 164 of the channel 168.
(27) Additionally, the rounded superior end 162 of the device 160 presses against cardia, thereby triggering release of satiety-inducing hormones, signaling the body to stop eating. The inflated device substantially fills the stomach cavity which maintains contact with the cardia. However, during food intake, the churning of the stomach walls will naturally squeeze the device 160, such that the superior end 162 will pressurize and apply greater force to the cardia.
(28) For device insertion, a lubricated, Teflon or similar material, thin-walled tube would be inserted down the esophagus, and partially into the stomach, with the device compressed and pre-loaded inside the tube. Then the device would be maintained in its location by using a foot-ended wire or similar obturator, to bear on the compressed mass, and the delivery tube would be pulled back up the esophagus, and extracted through the mouth, leaving the device in place. While the tube is removed, the resiliency of the material causes the device to spring open to its original/non-compressed shape. A valve (not shown) near the superior end may be provided for saline filling the body 161.
(29) For device removal, as seen in
(30) Another device 180 that has a flow-through channel and almost-entirely fills the stomach is shown in
(31) The device 180 consists of a collapsible tubular stent 182 surrounded by a generally annular foam body 184, and is seen pre-implant in
(32) The stent 182 is normally expanded, but can be compressed to a size that allows for insertion and removal through a tube 185 passed through the esophagus, as seen in
(33) The sponge like, foam body 184 (open or closed cell) surrounding the stent 182 fills the space across the stomach cavity, though does not extend the full length of the stomach, as seen in
(34) The foam can be compressed and held in place during implantation and explantation as in
(35) A still further device 200 that provides a flow-through space is shown in
(36) The device 200 is formed of a flexible material that allows it to be compressed and pre-loading into a delivery tube (not shown) for esophageal insertion into the stomach. Deployment of the device 200 within the stomach cavity permits expansion of the device into the position shown in
(37) The diameter and concavity of the bowl-shaped proximal end 204 allows it to contact the stomach cavity walls and intercept food and liquid entering through the esophageal sphincter. The proximal end 204 acts as a detention tray positioned just inside the stomach from the esophageal sphincter that presents a barrier to incoming food bound for the stomach, but which eventually overflows its contents into the stomach. A small drain hole 212 acts as an artificial stoma and permits a limited amount of food and liquid past the proximal end 204 and into the cavity of the body 202. From there, gastric juices mixed with the food particles and begin the process of breaking them down into chyme. The body 202 is sufficiently flexible so that contractions of the stomach muscles are transmitted therethrough. The diameter of the spherical pyloric member 208 is sufficiently large that it cannot pass through the pyloric sphincter.
(38) Because of the length of the body 202, and the curved shape of the device 200, the proximal end 204 contacts the walls around the esophageal junction, and against the cardia. In addition, the hollow leg 206 serves as an anti-rotational feature to help hold the device in place, and allow it to return to a normal position as shown, after peristaltic waves in the stomach.
(39) In a second embodiment seen in
(40) The second embodiment 200 has a tube 214 that extends between the drain hole 212 and an opposite surface of the body 202, on the convex side thereof. In this embodiment, food that passes through the drain hole 212 does not enter the interior of the inflated body 202, but instead passes to the opposite side. The tube 214 tethers the bowl-shaped proximal end 204 to the opposite surface of the balloon, so when saline-filled, the concave bowl shape is retained. As in the first embodiment, the amount of food caught by and contained in the concave bowl 204 is far less than can be held in an empty stomach. In both embodiments, when food enters the bowl 204 it accumulates and applies pressure to the cardia, thereby stimulating release of satiety-inducing hormones.
(41) Deployment of the device 200 within the stomach cavity is similar to the earlier embodiment, but once deployed in the cavity the user inflates the body 202 through a fill valve 216 provided in the concave proximal end 204. Removal of the inflated device 200 is accomplished by inserting a tube down the esophagus, and clippers down the tube. The device 200 can then be clipped to evacuate the saline, and a standard grabber can then be employed to pull the deflated balloon back into the tube for removal therewith. In the second embodiment, size adjustability is possible by removing or adding saline, whereas the first embodiment may be supplied in a few different sizes.
(42) Some food will normally leak out into the stomach, around the upper rim of the bowl 204, where it contacts the stomach lining. The remaining food passes through the centrally-located small stoma 212, and into the stomach. The inflated embodiment 200 is thought to have a more compliant stoma than the non-inflated version 200, so food passage can be somewhat easier.
(43)
(44) As with earlier devices, those shown in
(45)
(46) With reference again to
(47) The fill valve 312 at the proximal terminus of the tether 302 allows saline to be added though a detachable fill tube (not shown) inserted down the esophagus, and includes a self-closing slit to hold the saline inside the device 300. Details of an exemplary fill valve 312 will be provided below with reference to
(48) Now with particular reference to
(49) The largest balloon, the proximal positioning balloon 306, features an arcuate, generally semi-circular outer section 320 connected at either end to radial spoke sections 322 that meet in the middle along an axis of the structure through which the tether 302 passes. A shorter radial spoke section 324 extends between the outer section 320 and the convergence of the larger spoke sections 322 in the middle of the balloon 320, and generally extends along a plane that bisects the balloon into two symmetric halves. Two apertures 325 formed between the outer section 320 and the spoke sections 322, 324 permit passage of food therethrough such that the positioning balloon 306 does not present a solid barrier to churning movement of food within the stomach. As seen best in
(50) Finally, the pyloric balloon 310 has a generally spherical outer shape with a lumen 326 extending axially through the middle to create a donut shape. The lumen 326 through the center of the pyloric balloon permits normal egress of food from the stomach into the duodenum. The inflated pyloric balloon 310 cushions against the pylorus without making a tight seal, but intermittently sealing nonetheless. This tends to delay gastric emptying. As seen best in
(51)
(52)
(53) An exemplary fill valve 312 for use with the device 300 of
(54)
(55) While not shown, the outer surface of the intragastric devices disclosed herein may further include additional uneven surface features such as small rounded bumps or protrusions, quill-like extensions, dimples or recesses, and the like. These features, upon contact with the inner stomach wall of the patient may further trigger hormone release or otherwise aid the patient in feeling full. Such features may be particularly effective for those embodiments which stimulate the cardia. The examples in
(56) For instance,
(57) Another example of exterior stimulation features is seen in
(58)
(59) It should be noted that the embodiments shown in
(60) It should also be stated that any of the embodiments described herein may utilize materials that improve the efficacy of the device. For example, a number of elastomeric materials may be used including, but not limited to, rubbers, fluorosilicones, fluoroelastomers, thermoplastic elastomers, or any combinations thereof. The materials are desirably selected so as to increase the durability of the device and facilitate implantation of at least six months, and preferably more than 1 year.
(61) Material selection may also improve the safety of the device. Some of the materials suggested herein, for example, may allow for a thinner wall thickness and have a lower coefficient of friction than the current device which may aid in the natural passage of the balloon through the GI tract should the device spontaneously deflate.
(62) The implantable devices described herein will be subjected to clinical testing in humans. The devices are intended to treat obesity, which is variously defined by different medical authorities. In general, the terms overweight and obese are labels for ranges of weight that are greater than what is generally considered healthy for a given height. The terms also identify ranges of weight that have been shown to increase the likelihood of certain diseases and other health problems. Applicants propose implanting the devices as described herein into a clinical survey group of obese patients in order to monitor weight loss.
(63) The clinical studies will utilize the devices described above in conjunction with the following parameters.
(64) Materials:
(65) a. Silicone materials used include 3206 silicone for any shells, inflatable structures, or otherwise flexible hollow structures. Any fill valves will be made from 4850 silicone with 6% BaSo.sub.4. Tubular structures or other flexible conduits will be made from silicone rubber as defined by the Food and Drug Administration (FDA) in the Code of Federal Regulations (CFR) Title 21 Section 177.2600.
(66) Purposes:
(67) a. the devices are for human implant,
(68) b. the devices are intended to occupy gastric space while also applying intermittent pressure to various and continually changing areas of the stomach;
(69) c. the devices are intended to stimulate feelings of satiety, thereby functioning as a treatment for obesity.
(70) General Implant Procedures:
(71) a. The device is intended to be implanted transorally via endoscope into the corpus of the stomach.
(72) b. Implantation of the medical devices will occur via endoscopy.
(73) c. Nasal/Respiratory administration of oxygen and isoflurane to be used during surgical procedures to maintain anesthesia as necessary.
(74) One exemplary implant procedure is listed below.
(75) a. Perform preliminary endoscopy on the patient to examine the GI tract and determine if there are any anatomical anomalies which may affect the procedure and/or outcome of the study.
(76) b. Insert and introducer into the over-tube.
(77) c. Insert a gastroscope through the introducer inlet until the flexible portion of the gastroscope is fully exited the distal end of the introducer.
(78) d. Leading under endoscopic vision, gently navigate the gastroscope, followed by the introducer/over-tube, into the stomach.
(79) e. Remove gastroscope and introducer while keeping the over-tube in place.
(80) f. OPTIONAL: Place the insufflation cap on the over-tubes inlet, insert the gastroscope, and navigate back to the stomach cavity.
(81) g. OPTIONAL: Insufflate the stomach with air/inert gas to provide greater endoscopic visual working volume.
(82) h. Collapse the gastric implant and insert the lubricated implant into the over-tube, with inflation catheter following if required.
(83) i. Under endoscopic vision, push the gastric implant down the over-tube with gastroscope until visual confirmation of deployment of the device into the stomach can be determined.
(84) j. Remove the guide-wire from the inflation catheter is used.
(85) k. If inflated: Inflate the implant using a standard BioEnterics Intragastric Balloon System (BIB System) Fill kit.
(86) l. Using 50-60 cc increments, inflate the volume to the desired fill volume.
(87) m. Remove the inflation catheter via over-tube.
(88) n. Inspect the gastric implant under endoscopic vision for valve leakage, and any other potential anomalies. Record all observations.
(89) o. Remove the gastroscope from over-tube.
(90) p. Remove the over-tube from the patient.
(91) End Point Criteria:
(92) Weight Loss
(93) Comprehensive Metabolic Panel (CMP)
(94) HbA1C
(95) Lipid Panel
(96) Tissue Samples/Response
(97) Unless otherwise indicated, all numbers expressing quantities of ingredients, properties such as molecular weight, reaction conditions, and so forth used in the specification and claims are to be understood as being modified in all instances by the term about. Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary depending upon the desired properties sought to be obtained. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical parameter should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques.
(98) Notwithstanding that the numerical ranges and parameters setting forth the broad scope of the disclosure are approximations, the numerical values set forth in the specific examples are reported as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements.
(99) The terms a, an, the and similar referents used in the context of describing the invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range. Unless otherwise indicated herein, each individual value is incorporated into the specification as if it were individually recited herein. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., such as) provided herein is intended merely to better illuminate the invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the specification should be construed as indicating any non-claimed element essential to the practice of the invention.
(100) Groupings of alternative elements or embodiments of the invention disclosed herein are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other members of the group or other elements found herein. It is anticipated that one or more members of a group may be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims.
(101) Certain embodiments are described herein, including the best mode known to the inventors for carrying out the invention. Of course, variations on these described embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventor expects skilled artisans to employ such variations as appropriate, and the inventors intend for the invention to be practiced otherwise than specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described elements in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context.
(102) Furthermore, references may have been made to patents and printed publications in this specification. Each of the above-cited references and printed publications are individually incorporated herein by reference in their entirety.
(103) Specific embodiments disclosed herein may be further limited in the claims using consisting of or consisting essentially of language. When used in the claims, whether as filed or added per amendment, the transition term consisting of excludes any element, step, or ingredient not specified in the claims. The transition term consisting essentially of limits the scope of a claim to the specified materials or steps and those that do not materially affect the basic and novel characteristic(s). Embodiments of the invention so claimed are inherently or expressly described and enabled herein.
(104) In closing, it is to be understood that the embodiments of the invention disclosed herein are illustrative of the principles of the present invention. Other modifications that may be employed are within the scope of the invention. Thus, by way of example, but not of limitation, alternative configurations of the present invention may be utilized in accordance with the teachings herein. Accordingly, the present invention is not limited to that precisely as shown and described.